Effect of Administration of Tanshinone ⅡA on the No-Reflow in Patients with Acute Myocardial Infarction

GUO Zhangqiang,CHENG Zhong,LI Lun,WU Jie,BAI Yupeng,LIU Qiyun,LI Gang,GU Ye
DOI: https://doi.org/10.3969/j.issn.1001-1439.2011.03.010
2011-01-01
Journal of Clinical Cardiology
Abstract:Objective:To study the effects of tanshinone ⅡA on the no-reflow in patients with AMI,and therefore,provide new theory for the immunoregulation mechanism of tanshinone ⅡA in the AMI.Method:We prospectively studied 88 patients underwent acute myocardial infarction,who were random designated to no-reflow treated with tanshinone ⅡA group(28 cases) or without tanshinone ⅡA group(20 cases) and reflow without tanshinone ⅡA treated group(40 cases).The stable angina pectoris(30 cases) group was designated to the control group.TGF-β1 and the number of colony-forming units of endothelial progenitor cell(EPC) in the peripheral blood were measured on 4 weeks by ELISA and counted by phase-contrast microscope,respectively.Result:The level of TGF-β1 and EPC number in the AMI group were significantly lower than those in control group(P0.05),and there was statistical difference between the no-reflow group and reflow group.The amelioration of the decreased TGF-β1 level and EPC number in the no-reflow treated group and refolw group were significantly lower than those in the no-reflow without tanshinone ⅡA group(P0.05).Conclusion:Regulation of TGF-β1 and EPC by tanshinone ⅡA,suggesting a possible mechanism of tanshinone ⅡA in the immunoregulation role in the no-reflow phenomenon in the AMI.
What problem does this paper attempt to address?